Miniatura

Fitxers

BenaventE.pdf (667.75 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-01-01

Llicència de publicació

cc by (c) Benavent Palomares et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/174217

Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/antibiotics10010053

Resum

Background: To evaluate the efficacy and safety of long-term use of tedizolid in osteoarticular infections. Methods: Multicentric retrospective study (January 2017–March 2019) of osteoarticular infection cases treated with tedizolid. Failure: clinical worsening despite antibiotic treatment or the need of suppressive treatment. Results: Cases (n = 51; 59% women, mean age of 65 years) included osteoarthritis (n = 27, 53%), prosthetic joint infection (n = 17, 33.3%), and diabetic foot infections (n = 9, 18%); where, 59% were orthopedic device-related. Most frequent isolates were Staphylococcus spp. (65%, n = 47; S. aureus, 48%). Reasons for choosing tedizolid were potential drug-drug interaction (63%) and cytopenia (55%); median treatment duration was 29 days (interquartile range -IQR- 15–44), 24% received rifampicin (600 mg once daily) concomitantly, and adverse events were scarce (n = 3). Hemoglobin and platelet count stayed stable throughout treatment (from 108.6 g/L to 116.3 g/L, p = 0.079; and 240 × 109/L to 239 × 109/L, p = 0.942, respectively), also in the subgroup of cases with cytopenia. Among device-related infections, 33% were managed with implant retention. Median follow-up was 630 days and overall cure rate 83%; among failures (n = 8), 63% were device-related infections. Conclusions: Long-term use of tedizolid was effective, showing a better safety profile with less myelotoxicity and lower drug-drug interaction than linezolid. Confirmation of these advantages could make tedizolid the oxazolidinone of choice for most of osteoarticular infections.

Matèries

Diabetis, Interaccions dels medicaments

Matèries (anglès)

Diabetes, Drug interactions

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

BENAVENT PALOMARES, Eva, MORATA, Laura, ESCRIHUELA VIDAL, Francesc, REYNAGA, Esteban alberto, SOLDEVILA-BOIXADER, Laura, ALBIACH, Laia, PEDRO BOTET, Maria luisa, PADULLÉS ZAMORA, Ariadna, SORIANO VILADOMIU, Alex, MURILLO RUBIO, Óscar. Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs. _Antibiotics_. 2021. Vol. 10, núm. 1. [consulta: 24 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/174217]

Exportar metadades

JSON - METS

Compartir registre